Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Current Deferred Revenue (2016)

Historic Current Deferred Revenue for Amphastar Pharmaceuticals (AMPH) over the last 4 years, with Q3 2016 value amounting to $830000.0.

  • Amphastar Pharmaceuticals' Current Deferred Revenue rose 2908.24% to $830000.0 in Q3 2016 from the same period last year, while for Sep 2016 it was $830000.0, marking a year-over-year increase of 2908.24%. This contributed to the annual value of $643000.0 for FY2015, which is 9541.14% down from last year.
  • As of Q3 2016, Amphastar Pharmaceuticals' Current Deferred Revenue stood at $830000.0, which was up 2908.24% from $1.7 million recorded in Q2 2016.
  • Amphastar Pharmaceuticals' 5-year Current Deferred Revenue high stood at $14.6 million for Q3 2014, and its period low was $643000.0 during Q4 2013.
  • For the 4-year period, Amphastar Pharmaceuticals' Current Deferred Revenue averaged around $4.1 million, with its median value being $830000.0 (2016).
  • In the last 5 years, Amphastar Pharmaceuticals' Current Deferred Revenue skyrocketed by 207931.57% in 2014 and then crashed by 9559.47% in 2015.
  • Over the past 4 years, Amphastar Pharmaceuticals' Current Deferred Revenue (Quarter) stood at $643000.0 in 2013, then soared by 2079.32% to $14.0 million in 2014, then plummeted by 95.41% to $643000.0 in 2015, then increased by 29.08% to $830000.0 in 2016.
  • Its Current Deferred Revenue stands at $830000.0 for Q3 2016, versus $1.7 million for Q2 2016 and $643000.0 for Q1 2016.